Responses
Clinical/translational cancer immunotherapy
Original research
First-line treatment of unresectable or metastatic HER2 positive esophagogastric adenocarcinoma: liquid biomarker analysis of the phase 2 INTEGA trial
Compose a Response to This Article
Other responses
No responses have been published for this article.